Home > Business > PTI > Report

Ranbaxy Labs get US FDA approval for drug

September 16, 2003 18:31 IST
Last Updated: September 16, 2003 18:47 IST


Ranbaxy Laboratories on Tuesday said it had received approval from US Food and Drug Administration to market a semi synthetic cephalosporin Panixine DisperDose, a generic version of Ceph International Corp, Keflex.

The company has received approval for Cephalexin for oral suspension 125 mg and 250 mg total market for which had been valued at $32 million in US.

Cephalexin represents the second most prescribed anti-infective agent in US for clinical indications such as respiratory tract infections, skin and skin structure infections, bone infections and genit-urinary tract infections.

This new dosage form of Cephalexin will be especially beneficial to patients who cannot swallow solid dosage forms and as alternative to the oral suspension Cephalexin, a Ranbaxy statement said.

Panixine DisperDose will be distributed by Ranbaxy Brand Promotion Division in US under Ranbaxy label.

Commenting on the approval, Ranbaxy Pharmaceuticals Inc, president Dipak Chattaraj said: "This addition to the already extensive line of anti-infectives available from Ranbaxy once again demonstrates the company's commitment to this therapeutic category through this value added dosage form that will provide a worthwhile contribution to patient care and to the overall US healthcare system."

Article Tools

Email this Article

Printer-Friendly Format

Letter to the Editor




Related Stories


FDA OKs Ranbaxy's Loratidine

India to rule Loratidine market

Ranbaxy unit, US firm ink pact



People Who Read This Also Read


Highlights of SC verdict

Stock picks for September 17

Assessing mutual fund managers






© Copyright 2003 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.











Copyright © 2003 rediff.com India Limited. All Rights Reserved.